Our global businesses – generics, biosimilars, research services and novel biologics research, develop and manufacture innovative biopharmaceutical medicines for unmet medical needs and branded formulations cater to the Indian market. We truly believe drug innovation and therapy cost must interact effectively in a new financial matrix. Biocon’s business strategy of delivering affordable innovation is well aligned with this emerging paradigm. Biocon’s fully integrated business model spans the entire drug value chain, from pre-clinical discovery to clinical development and through to commercialisation.